Instructions for CME/NCPD: Complete the pre-test, listen to the
audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name
and email address on the pre-test, evaluation and post-test. If you
close your internet browser without completing the post test, you
will have ONE more opportunity to complete. A score of 70% must be
achieved on the post test to receive continuing education credits.
If you do not pass the post test after two attempts, you will not be
eligible to try again. Once you complete the evaluation form and
score 70% or higher on your post test, you will automatically be
given your certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
|
|
Audience:
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by an
educational grant from
Regeneron Pharmaceuticals
Description:
Retinal diseases are those that affect the retina, or the back layer
of your eye. A retinal disease can affect any part of the retina,
including the macula. Many retinal diseases cause symptoms that
affect a patient's vision. It’s important to find and treat diseases
of the retina, as many of them can cause blindness or low vision if
they aren’t treated. Retinal diseases including age-related macular
degeneration (AMD) and diabetic retinopathy/diabetic macular edema
(DR/DME) pose a significant burden to patients and the health care
system. Fortunately for patients with AMD and DR/DME, intravitreal
anti-VEGF therapy has revolutionized the treatment of retinal
disease and improved patient outcomes, especially in the area of
dosing intervals which have improved quality of life for patients
with less frequent injections. This live webinar series will take a
close look at the latest data and updates on anti-VEGF therapies in
both DR/DME and AMD.
Upon completion of this
activity, participants will be able to:
-
Assess the clinical and economic burden of age-related macular
degeneration (AMD), including factors that contribute to poor
prognosis and increased costs
-
Review the mechanism of action, pharmacokinetics, efficacy, and
dosing intervals of anti-vascular endothelial growth factor (VEGF)
agents in the treatment of AMD
-
Analyze current evidence from recent clinical studies to
differentiate anti-VEGF therapies and identify appropriate
therapies and dosing schedules for AMD patients
-
Evaluate clinical guideline updates and recommendations for the
use of anti-VEGF therapies in AMD
-
Explore how treatment innovations are improving durability,
efficacy, and patient outcomes
-
Examine opportunities for managed care professionals to
collaborate with other health care providers to improve access
to care for patients with AMD, including addressing barriers to
care such as cost, transportation, and lack of access to
specialty providers
Faculty:
Jordan M. Graff, MD, FACS
Surgeon & Partner, BDP Eye Center – Retina Division
Clinical Assistant Professor of Ophthalmology, U of A Phx
Clinical Assistant Professor, Creighton University
jgraff@bdpec.com
Disclosure Information:
As accredited providers, NAMCP and AAMCN must ensure balance,
independence, objectivity, and scientific rigor in all of their
activities. All faculty participating in this activity are required
to disclose to NAMCP/AAMCN any financial relationships with
ineligible companies. NAMCP/AAMCN in turn discloses all relevant
financial conflicts to the learners. NAMCP/AAMCN disclosure policy
adheres to The Standards for Integrity and Independence in
Accredited Continuing Education. All relevant conflicts of interest
have been mitigated prior to the commencement of the activity. See
below for conflicts of interest.
Disclosures (Relevant Financial Relationships with Ineligible
Companies in the Last 24 Months):
Dr. Graff has served as a consultant for Alimera, Hi-Health,
IvericBio, Ocular Therapeutix, Regeneron, RegenxBio, and Roche/Genentech.
He has received research/grant support from Kyowa Kirin, Ocular
Therapeutix, Regeneron, Regenxbio, and Roche/Genentech. All relevant
conflicts of interest have been mitigated.
Planning Committee Disclosures (Relevant Financial Relationships
with Ineligible Companies in the Last 24 Months):
Bill Williams, MD has no relevant financial relationship with an
ineligible company to disclose.
Jeremy Williams has no relevant financial relationship with an
ineligible company to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationship
with an ineligible company to disclose.
NAMCP and/or the presenter has copyright or has received permissions
for use of materials provided in this activity.
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring
material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
requirements.
NAMCP and/or this website do not provide medical advice, diagnosis,
or treatment. NAMCP does not endorse or imply endorsement of the
content on any linked website. This website is to be used as an
informational resource. With any health-related concern, consult
with your physician or healthcare professional.
This activity is supported by an educational grant from
Regeneron Pharmaceuticals
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
professional.
Click Here To Continue |